{"id":"linezolid-zyvox","safety":{"commonSideEffects":[{"rate":"2-3","effect":"Thrombocytopenia"},{"rate":"3-10","effect":"Nausea"},{"rate":"2-11","effect":"Diarrhea"},{"rate":"0.5-11","effect":"Headache"},{"rate":null,"effect":"Peripheral neuropathy (with prolonged use)"},{"rate":null,"effect":"Optic neuropathy (with prolonged use)"},{"rate":null,"effect":"Serotonin syndrome (drug interaction risk)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Linezolid is an oxazolidinone antibiotic that binds to the bacterial 50S ribosomal subunit and blocks the initiation of protein synthesis. This mechanism is bacteriostatic, halting bacterial growth and allowing the immune system to clear the infection. It is effective against both gram-positive and some gram-negative bacteria, including resistant strains such as MRSA and VRE.","oneSentence":"Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:05.687Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vancomycin-resistant Enterococcus faecium (VRE) infections"},{"name":"Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)"},{"name":"Complicated skin and soft tissue infections caused by susceptible gram-positive bacteria"},{"name":"Community-acquired pneumonia caused by susceptible pathogens"}]},"trialDetails":[{"nctId":"NCT06958835","phase":"NA","title":"Linezolid Plus Standard of Care","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-10-06","conditions":"Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)","enrollment":606},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT06192160","phase":"PHASE2","title":"Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-11","conditions":"Pulmonary Tuberculosis","enrollment":315},{"nctId":"NCT07477119","phase":"PHASE4","title":"Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"Marco Schiuma","startDate":"2026-03","conditions":"Linezolid, Tuberculosis Multi Drug Resistant Active, Therapeutic Drug Monitoring (TDM)","enrollment":150},{"nctId":"NCT05548426","phase":"PHASE2","title":"Linezolid for Syphilis Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-09-28","conditions":"Syphilis","enrollment":24},{"nctId":"NCT07435051","phase":"PHASE3","title":"Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-05-01","conditions":"Osteomyelitis (Refractory)","enrollment":280},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT07209761","phase":"PHASE3","title":"A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-10-16","conditions":"Pulmonary Tuberculosis","enrollment":532},{"nctId":"NCT05571722","phase":"PHASE4","title":"Linezolid or Vancomycin Surgical Site Infection Prophylaxis","status":"RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2024-11-12","conditions":"Antibiotic Prophylaxis, General Surgery","enrollment":1160},{"nctId":"NCT07170800","phase":"PHASE2","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","status":"RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2025-09-19","conditions":"Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":60},{"nctId":"NCT07372781","phase":"PHASE2","title":"Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Chest Hospital","startDate":"2026-01-01","conditions":"Monotherapy, Mycobacterium Abscessus Infection","enrollment":24},{"nctId":"NCT06590428","phase":"NA","title":"Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis","status":"RECRUITING","sponsor":"Albert Einstein College of Medicine","startDate":"2026-03","conditions":"Rifampin-resistant Tuberculosis, Drug-resistant Tuberculosis","enrollment":280},{"nctId":"NCT06441006","phase":"PHASE2, PHASE3","title":"Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-10-03","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":400},{"nctId":"NCT07332325","phase":"PHASE3","title":"STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":"Sepsis, Tuberculosis","enrollment":344},{"nctId":"NCT07301294","phase":"PHASE4","title":"Microbiological Characteristics of Biofilm on Double J Ureteral Stents After Lithotripsy.","status":"NOT_YET_RECRUITING","sponsor":"Menoufia University","startDate":"2026-01-01","conditions":"Double J Stent","enrollment":100},{"nctId":"NCT03012360","phase":"PHASE4","title":"Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2018-02-08","conditions":"Mechanical Ventilation Complication, Critical Illness","enrollment":103},{"nctId":"NCT05206500","phase":"PHASE4","title":"NextGen - Clinical Implication of Next Generation Sequencing","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2022-05-17","conditions":"Urinary Tract Infections","enrollment":100},{"nctId":"NCT07268664","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2025-12-01","conditions":"Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis","enrollment":120},{"nctId":"NCT06602245","phase":"","title":"Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis","status":"COMPLETED","sponsor":"Efferon JSC","startDate":"2024-10-21","conditions":"Sepsis, Septic Shock","enrollment":30},{"nctId":"NCT05383742","phase":"PHASE2","title":"Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Tuberculous Meningitis","enrollment":330},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT07228702","phase":"PHASE1","title":"Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Vancouver Coastal Health","startDate":"2025-11","conditions":"Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection","enrollment":1},{"nctId":"NCT07230041","phase":"","title":"In Vivo Antibiotics Removal During Hemoadsorption Cartridges and Continuous Renal Replacement Therapy in the Intensive Care Unit","status":"RECRUITING","sponsor":"Niguarda Hospital","startDate":"2025-01-15","conditions":"Septic Shock","enrollment":20},{"nctId":"NCT07227779","phase":"PHASE2","title":"B-PaLMZ for TB Meningitis","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-02-15","conditions":"Tuberculous Meningitis","enrollment":240},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT07204522","phase":"","title":"Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-09-22","conditions":"Febrile Neutropenia","enrollment":20},{"nctId":"NCT07198685","phase":"NA","title":"6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":"Treat to Target, Treatment Duration","enrollment":52},{"nctId":"NCT07191834","phase":"","title":"A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":"Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM), Pretomanid","enrollment":60},{"nctId":"NCT05369052","phase":"PHASE3","title":"Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)","status":"RECRUITING","sponsor":"MicuRx","startDate":"2022-05-03","conditions":"Diabetic Foot Infection","enrollment":865},{"nctId":"NCT02333799","phase":"PHASE3","title":"A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2015-03","conditions":"Pulmonary Tuberculosis","enrollment":109},{"nctId":"NCT06649721","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-11-27","conditions":"Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis","enrollment":120},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT07138521","phase":"PHASE4","title":"Optimizing Linezolid Dosing in Patients With Advanced Renal Impairment: a Therapeutic Drug Monitoring-based Evaluation","status":"NOT_YET_RECRUITING","sponsor":"Alexandria University","startDate":"2025-10-15","conditions":"Kidney Disease","enrollment":50},{"nctId":"NCT07126639","phase":"NA","title":"A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-01","conditions":"Efficacy and Safety","enrollment":200},{"nctId":"NCT04310930","phase":"PHASE2, PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","enrollment":300},{"nctId":"NCT05007821","phase":"PHASE2","title":"Linezolid Dosing Strategies in Drug-Resistant TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-08-11","conditions":"Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary","enrollment":138},{"nctId":"NCT03176134","phase":"PHASE3","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-20","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":100},{"nctId":"NCT06761131","phase":"","title":"Compare Linezolid-Induced Thrombocytopenia in Patients With Normal Renal Function Versus Impaired Renal Function","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-05-20","conditions":"Thrombocytopaenia, Impaired Renal Function","enrollment":60},{"nctId":"NCT06423898","phase":"PHASE4","title":"Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-09","conditions":"Endocarditis, Infective","enrollment":284},{"nctId":"NCT05069974","phase":"PHASE3","title":"Alternative Antibiotics for Syphilis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2021-10-14","conditions":"Early Latent Syphilis, Primary Syphilis, Secondary Syphilis","enrollment":224},{"nctId":"NCT07076225","phase":"PHASE3","title":"Ultra-Short Regimen for Elderly DS-TB","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-07-25","conditions":"Pulmonary Tuberculosis","enrollment":300},{"nctId":"NCT05944458","phase":"PHASE4","title":"Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2023-08-01","conditions":"Linezolid, Antioxidant, Thrombocytopenia","enrollment":250},{"nctId":"NCT06959667","phase":"","title":"Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-04-15","conditions":"Methicillin-susceptible S. Aureus (MSSA), Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA), Complicated Skin and Soft Tissue,cSSTI","enrollment":144},{"nctId":"NCT06921213","phase":"PHASE2","title":"Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis","status":"NOT_YET_RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2025-10-01","conditions":"Syphilis, Congenital","enrollment":90},{"nctId":"NCT03828201","phase":"PHASE2","title":"Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB","status":"RECRUITING","sponsor":"Boston University","startDate":"2022-06-07","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":220},{"nctId":"NCT00664313","phase":"PHASE1, PHASE2","title":"TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2009-04","conditions":"Multi-drug Resistant Tuberculosis, Extensively Drug Resistant Tuberculosis","enrollment":36},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":"Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB","enrollment":1050},{"nctId":"NCT06081361","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2023-12-22","conditions":"Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":186},{"nctId":"NCT06058299","phase":"PHASE2","title":"Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Global Alliance for TB Drug Development","startDate":"2023-10-24","conditions":"Pulmonary TB, Pulmonary Tuberculosis, Drug Sensitive Tuberculosis","enrollment":309},{"nctId":"NCT03896685","phase":"PHASE3","title":"Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)","status":"COMPLETED","sponsor":"Médecins Sans Frontières, France","startDate":"2020-04-06","conditions":"Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary Tuberculoses","enrollment":323},{"nctId":"NCT02754765","phase":"PHASE3","title":"Evaluating Newly Approved Drugs for Multidrug-resistant TB","status":"COMPLETED","sponsor":"Médecins Sans Frontières, France","startDate":"2016-12","conditions":"Tuberculosis, Multidrug-Resistant, Infection, Bacterial, Pulmonary Tuberculoses","enrollment":754},{"nctId":"NCT06811025","phase":"PHASE1, PHASE2","title":"Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Chest Hospital","startDate":"2024-02-01","conditions":"Tuberculosis, Meningitis","enrollment":24},{"nctId":"NCT06811012","phase":"PHASE1, PHASE2","title":"Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Chest Hospital","startDate":"2024-01-31","conditions":"Tuberculosis, Bone, Joint","enrollment":24},{"nctId":"NCT02365623","phase":"PHASE2","title":"An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-02-18","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":6},{"nctId":"NCT05534750","phase":"PHASE2","title":"Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-20","conditions":"Tuberculosis, Multidrug Resistant Tuberculosis","enrollment":60},{"nctId":"NCT03583333","phase":"PHASE3","title":"Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-18","conditions":"Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia","enrollment":274},{"nctId":"NCT05764876","phase":"PHASE3","title":"Repurposing Clinically Approved Drugs for Yaws with an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2023-03-14","conditions":"Yaws, Cutaneous Ulcer","enrollment":465},{"nctId":"NCT06709196","phase":"PHASE4","title":"Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-01-07","conditions":"Cystectomy, Bladder Cancer Requiring Cystectomy, Postoperative Infections","enrollment":248},{"nctId":"NCT02619994","phase":"PHASE2","title":"Treatment Shortening of MDR-TB Using Existing and New Drugs","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-01","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":214},{"nctId":"NCT06729619","phase":"","title":"Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xueyan Cui","startDate":"2024-06-03","conditions":"Intracranial Infection, Central Infection","enrollment":200},{"nctId":"NCT03220074","phase":"PHASE4","title":"Linezolid for Treatment of Nontuberculous Mycobacterial Diseases","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-12-15","conditions":"Non-tuberculous Mycobacterial Infections","enrollment":40},{"nctId":"NCT04717908","phase":"NA","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2021-01-20","conditions":"Multidrug Resistant Tuberculosis","enrollment":89},{"nctId":"NCT03867136","phase":"PHASE4","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2020-06-01","conditions":"Multidrug Resistant Tuberculosis","enrollment":354},{"nctId":"NCT06674291","phase":"","title":"Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)","status":"NOT_YET_RECRUITING","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2024-11-30","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":222},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT02269319","phase":"PHASE2","title":"MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection","status":"COMPLETED","sponsor":"MicuRx","startDate":"2015-02","conditions":"Bacterial Infections","enrollment":120},{"nctId":"NCT04021121","phase":"PHASE2","title":"Adjunctive Linezolid for the Treatment of Tuberculous Meningitis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-05-05","conditions":"Tuberculosis, Meningeal","enrollment":40},{"nctId":"NCT04062201","phase":"PHASE3","title":"Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care","status":"COMPLETED","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2019-08-22","conditions":"Tuberculosis, Pre-XDR-TB, Extensively Drug-Resistant Tuberculosis","enrollment":402},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":"Staphylococcus Aureus Bacteremia","enrollment":290},{"nctId":"NCT06476210","phase":"PHASE4","title":"The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)","status":"RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2024-06","conditions":"Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT06444802","phase":"PHASE3","title":"Model-informed Precision Dosing for Linezolid","status":"NOT_YET_RECRUITING","sponsor":"University of Hamburg-Eppendorf","startDate":"2024-09-01","conditions":"Gram-Positive Bacterial Infections","enrollment":28},{"nctId":"NCT03942354","phase":"","title":"Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2019-09-01","conditions":"Multidrug Resistant Tuberculosis","enrollment":137},{"nctId":"NCT02589782","phase":"PHASE2, PHASE3","title":"Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2017-01","conditions":"Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis, Tuberculosis, Pulmonary","enrollment":552},{"nctId":"NCT04207112","phase":"PHASE2, PHASE3","title":"Economic Evaluation of New MDR TB Regimens","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2020-10-20","conditions":"Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis, Pulmonary Tuberculoses","enrollment":73},{"nctId":"NCT05381194","phase":"PHASE4","title":"BPaL(M) Regimen for the Treatment of MDR/RR-TB","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-12-13","conditions":"Multidrug- and Rifampicin-resistant Tuberculosis","enrollment":80},{"nctId":"NCT06291181","phase":"NA","title":"Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University Hospitals","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-01-01","conditions":"Staphylococcus Aureus","enrollment":265},{"nctId":"NCT04145258","phase":"PHASE3","title":"Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-02-07","conditions":"Tuberculous Meningitis","enrollment":768},{"nctId":"NCT05040126","phase":"PHASE3","title":"Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2021-10-07","conditions":"Pre-Extensively Drug-Resistant Pulmonary TB, Treatment Intolerant Multidrug-Resistant Pulmonary TB, Non-responsive Multidrug-Resistant Pulmonary TB","enrollment":400},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":"Endocarditis","enrollment":20},{"nctId":"NCT06126263","phase":"","title":"Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections","status":"UNKNOWN","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2023-01-01","conditions":"Streptococcal Sepsis, Invasive Group A Beta-Haemolytic Streptococcal Disease, Necrotizing Soft Tissue Infection","enrollment":1000},{"nctId":"NCT00501150","phase":"NA","title":"Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2005-09","conditions":"Gram-positive Bacterial Infections, Staphylococcal Infections","enrollment":211},{"nctId":"NCT03537495","phase":"PHASE2","title":"Pharmacokinetic Study of Linezolid for TB Meningitis","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2021-06-21","conditions":"Tuberculosis, Meningeal, Linezolid","enrollment":36},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT03474198","phase":"PHASE2, PHASE3","title":"Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis","status":"COMPLETED","sponsor":"University College, London","startDate":"2018-03-21","conditions":"Tuberculosis, Pulmonary","enrollment":675},{"nctId":"NCT05293132","phase":"PHASE2, PHASE3","title":"Effect of Montelukast Versus Co Enzyme in Sepsis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-02-01","conditions":"Sepsis","enrollment":90},{"nctId":"NCT05944445","phase":"","title":"The Incidence of Linezolid-induced Thrombocytopenia (LIT) in Critically Ill Patients, the Risk Factors for LIT","status":"UNKNOWN","sponsor":"Helwan University","startDate":"2023-07-13","conditions":"Thrombocytopenia; Drugs","enrollment":310},{"nctId":"NCT03086486","phase":"PHASE3","title":"Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2017-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":181},{"nctId":"NCT01734694","phase":"PHASE4","title":"Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2011-10","conditions":"Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis","enrollment":100},{"nctId":"NCT05813951","phase":"NA","title":"Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-12-02","conditions":"Treatment Efficacy","enrollment":140},{"nctId":"NCT05801484","phase":"NA","title":"Pharmacokinetics and Pharmacodynamics of Linezolid Continuous and Intermittent Administration","status":"UNKNOWN","sponsor":"Cluj Municipal Clinical Hospital","startDate":"2022-07-01","conditions":"Side-effect of Antibiotic, Efficacy, Pharmacokinetics","enrollment":60},{"nctId":"NCT02660554","phase":"NA","title":"Trial of MRSA Polymerase Chain Reaction for Pneumonia","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-01","conditions":"Pneumonia, Methicillin-Resistant Staphylococcus Aureus","enrollment":45},{"nctId":"NCT05306223","phase":"PHASE4","title":"A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2022-05-10","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":212},{"nctId":"NCT03747497","phase":"PHASE2","title":"Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection","status":"COMPLETED","sponsor":"MicuRx","startDate":"2018-11-15","conditions":"Skin Diseases, Bacterial, Gram-Positive Bacterial Infections","enrollment":196},{"nctId":"NCT03830671","phase":"PHASE4","title":"The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"Beijing Chest Hospital","startDate":"2019-03-08","conditions":"Multi-drug Resistant Tuberculosis","enrollment":515},{"nctId":"NCT05494957","phase":"PHASE4","title":"Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2022-08-05","conditions":"Nontuberculous Mycobacterial Lung Disease","enrollment":40},{"nctId":"NCT05354635","phase":"","title":"Therapeutic Follow-up of Antibiotics in Pediatric Intensive Care","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2022-06","conditions":"Intensive Care Units, Pediatric","enrollment":280},{"nctId":"NCT05339802","phase":"PHASE2","title":"A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-02-16","conditions":"Skin Infection","enrollment":90},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":"Other Infectious Diseases","enrollment":100}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"PLASMA CELL MYELOMA RECURRENT"},{"count":1,"reaction":"PSYCHOTIC DISORDER"},{"count":1,"reaction":"SEROTONIN SYNDROME"}],"_approvalHistory":[],"publicationCount":57,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zyvox, linezolid"],"phase":"marketed","status":"active","brandName":"linezolid (Zyvox)","genericName":"linezolid (Zyvox)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Linezolid (Zyvox) is a small molecule that inhibits the bacterial 70S ribosome, classified as an inhibitor. It is used to treat various bacterial infections, including osteomyelitis, pulmonary tuberculosis, bacterial pneumonia, prosthetic joint infection, and prosthetic infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}